ArticlePregnancy (Hoboken, N.J.)2026
The taper sign: Sonographic representation of uterine dehiscence in severe cases of placenta accreta spectrum.
Article in Pregnancy (Hoboken, N.J.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Prenatal diagnosis of placenta accreta spectrum (PAS) depends on reliable ultrasound markers and skilled image interpretation. Existing PAS markers emphasize placental features suggestive of abnormal adherence and require advanced image optimization. However, emerging hypotheses suggest that uterine dehiscence-not placental invasion-is the central mechanism underlying PAS, particularly in severe (Grade 3) disease. Despite this, few established ultrasound markers address this uterine dehiscence. We describe a novel ultrasound marker, the taper sign, which uniquely represents the uterine dehiscence in severe PAS with anterior placenta previa, and outline a standardized technique for image acquisition and interpretation. Methods: This descriptive report details the sonographic appearance of the taper sign on grayscale ultrasound in pregnancies with anterior placenta previa and prior cesarean delivery with surgically and histopathologically confirmed Grade 3 PAS. Ultrasound images from cases at our center were reviewed to characterize the morphologic features of the taper sign and define optimal imaging parameters. Representative images illustrate this novel marker and the required anatomical landmarks. Results: The taper sign is characterized by progressive myometrial thinning until it disappears at the level of the prior cesarean scar, producing a wedge-shaped appearance; this is distinct from previously described PAS markers. It is best seen using transvaginal ultrasound with a partially full bladder. Beginning in a midsagittal 2D grayscale view of the cervix, the anterior cervical lip is traced proximally as it transitions into the lower uterine segment myometrium. With the placenta previa bulging anteriorly, the overlying myometrium tapers to a point, terminating at the margin of the uterine dehiscence. This correlates with the deepest placental infiltration seen in Grade 3 PAS. In our experience, the taper sign is easily obtained and consistently identified in Grade 3 PAS with anterior placenta previa and prior cesarean delivery. Conclusion: The taper sign represents a novel ultrasound marker of severe PAS, reflecting the distinct wedge-like appearance of attenuated myometrium as it terminates at the uterine dehisence. This report provides a standardized description and imaging protocol to facilitate recognition of patients at increased risk for severe maternal morbidity. Ongoing studies aim to validate this marker's diagnostic performance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.